XNAS
LTGO
Market cap1.27bUSD
Sep 21, Last price
21.11USD
1D
-6.39%
IPO
13.74%
Name
Latigo Biotherapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
Net income
CFO
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Key people
Nancy Stagliano
Chairman of the Board
Desmond Padhi
Interim Chief Executive Officer, Director
Bryan Moyer
Co-Founder, Senior Vice President - Discovery
Holly Carlisle
Vice President - Translational Science
Mike Kaufman
Vice President - Chemistry
Valuation
No data to show